INTRODUCTION

Exposure to high altitude induces a decrease in oxygen pressure along the gradient from ambient air to cell mitochondria. The degree of hypoxemia is aggravated by the progressive decrease in atmospheric PO$_2$ so that the severity of tissue hypoxia increases with altitude. Physical exercise is a potent factor that aggravates the level of hypoxemia since, at high altitude, arterial PO$_2$ decreases when the intensity of exercise increases (West et al., 1983). This phenomenon has been clearly linked, at least in part, to a diffusion limitation in the lungs (Wagner, 2010; West et al., 1983). Two factors may be responsible for this limitation: (1) cardiac output increases with exercise intensity, causing a decrease of blood transit time in the pulmonary capillaries, hence reducing the time required...
for oxygen diffusion through the alveolo-capillary barrier; (2) due to a lower arterial O₂ content, peripheral O₂ extraction increases and PO₂ in the venous blood coming back to the lungs is lowered, rendering a proper reloading of O₂ in the capillaries more difficult (Mollard et al., 2007; Van Thienen & Hespel, 2016).

The myocardium is very sensitive to O₂ availability, especially when energetic demand is high such as during exercise. Therefore, the myocardium is submitted to a high constraint in terms of O₂ availability when exposed to both hypoxia and intense exercise. In this matter, if the maximal work of myocardium depends on mitochondrial O₂ content, the latter itself follows the variation of venous PO₂ (Gnaiger et al., 1995; Sutton et al., 1988), so we could assume that myocardial venous PO₂ is a valuable index of cardiac O₂ consumption, even if it is not likely to be linear.

Paradoxically, in alpinists exercising in extreme conditions over the altitude of 8000 m with an arterial PO₂ of around 35 mmHg, no cardiac failure, coronary insufficiency, angina pectoris or myocardial infarct has ever been reported (Mallet et al., 2021; Reeves et al., 1987). In parallel, heart rate at high altitude, although increasing at submaximal exercise for any level of workload, is greatly reduced at maximal exercise (Richalet, 2016), hereby protecting the myocardium against a too high energy consumption in conditions of low O₂ availability. An important series of studies in animals and humans have been performed to explain this decrease in maximal heart rate and developed the hypothesis of a down-regulation of beta-adrenergic receptors in the myocardium in prolonged exposure to hypoxia, together with an increase in parasymathetic influence (Antezana et al., 1994; Boushel et al., 2001; Favret & Richalet, 2007; Favret et al., 2001; Hartley et al., 1974; Kacimi et al., 1993; León-Velarde et al., 2001; Richalet, Mehdioi, et al., 1988; Siebenmann et al., 2017; Voelkel et al., 1981). This modulation of cardiac receptors would reduce the chronotropic response to the hypoxia-induced adrenergic activation and protect the myocardium in these extreme conditions (Richalet, 2016).

The present study aims to develop a model of O₂ transport in the myocardium at exercise in hypoxia in acclimatized subjects in order to demonstrate that the decrease in maximal heart rate at high altitude is necessary for the survival of myocardial tissue in these extreme conditions.

2 | MATERIAL AND METHODS

2.1 | Model description

Monitoring the level of oxygenation of the myocardial tissue would require measuring PO₂ within the tissue, which is not readily feasible in humans exercising in altitude conditions. Therefore, we aimed to determine an alternative method that would give us an indirect measure of tissue and mitochondrial oxygenation, represented by myocardial venous blood PO₂. A model of O₂ transport to the myocardium is given in Figure 1. Along the myocardial capillary, blood PO₂ is progressively decreasing from the arterial to the venous end while O₂ is diffusing to the tissue. We can assume that end-capillary PO₂ is in equilibrium with tissue PO₂, therefore, venous PO₂ equal to end-capillary PO₂, would be a reliable substitute to tissue PO₂ (Gnaiger et al., 1995; Herrmann & Feigl, 1992; Rubio & Berne, 1975; Sutton et al., 1988). The objective is therefore to calculate myocardial venous PO₂, a marker of myocardial tissue oxygenation, as a function of altitude in the condition of maximal exercise.

2.2 | Determinants of myocardial tissue PO₂

Myocardial tissue PO₂ is the result of O₂ consumption and O₂ availability. Oxygen consumption is determined by the cardiac mechanical power of the left and right ventricles (WLV and WRV), which depends on heart rate (HR), stroke volume (SV), and mean ejection pressure of each ventricle, in the aorta and in the pulmonary artery (PejAo and PejPa, respectively) (Opie, 1991):

\[
W_{LV} = HR \times SV \times PejAo \quad \text{and} \quad W_{RV} = HR \times SV \times PejPa
\]

Myocardial O₂ consumption (VO₂) is linked to cardiac mechanical power by the energetic equivalent of O₂ for the myocardium EE (Han et al., 2019):

\[
\text{O}_2 \text{ consumption} = W_{LV} \times \text{PejAo} \quad \text{and} \quad W_{RV} = HR \times SV \times PejPa
\]

**FIGURE 1** Model of oxygen handling in the myocyte. Tissue PO₂ (PtO₂) depends on the balance between O₂ availability after diffusion from the capillary and O₂ consumption by the myocyte. O₂ consumption is determined by cardiac mechanical power, which mainly depends on three factors: Heart rate (HR), stroke volume (SV), and mean ejection pressure (Pej).
\[ \dot{V}O_2 = EE \times (W_{LV} + W_{RV}) = EE \times HR \times SV \times (PejA_o + PejP_a) \] (1)

From the O\textsubscript{2} transport side, O\textsubscript{2} consumption can be derived from myocardial blood flow (Q) and myocardial arterio-venous difference in O\textsubscript{2} content (Ca–Cv), using the Fick equation:

\[ \dot{V}O_2 = Q \times (Ca - Cv) \] or \[ \dot{V}O_2 = \dot{Q} \times 1.34 \times [Hb] \times (SaO_2 - SvO_2) \] (2)

where [Hb] is the blood concentration of hemoglobin, SaO\textsubscript{2} and SvO\textsubscript{2} are the O\textsubscript{2} saturation in the arterial and myocardial venous blood, respectively.

Combining Equations (1) and (2), it comes:

\[ \dot{V}O_2 = EE \times HR \times SV \times (PejA_o + PejP_a) = \dot{Q} \times 1.34 \times [Hb] \times (SaO_2 - SvO_2) \]

This equation can be rewritten as follows:

\[ HR = \frac{\dot{Q} \times [Hb] \times (SaO_2 - SvO_2)}{A} \times A \] (3)

where

\[ A = \frac{1.34}{EE \times SV \times (PejA_o + PejP_a)} \]

Let us write this equation for heart rate at maximal exercise in normoxic (mn) and hypoxic (mh) conditions:

\[ HR_{mn} = \dot{Q}_{mn} \times [Hb]_{mn} \times (Samn - Svnn) \times Amn \]

\[ HR_{mh} = \dot{Q}_{mh} \times [Hb]_{mh} \times (Samh - Svnm) \times Amh \]

and the ratio

\[ HR_{mh} \times \frac{Amh}{Amn} \]

\[ HR_{mn} = \frac{\dot{Q}_{mn} \times [Hb]_{mn} \times (Samh - Svnm)}{[Hb]_{mn} \times (Samn - Svnn) \times Amh} \] (4)

In order to estimate HR\textsubscript{mh} as a function of HR\textsubscript{mn}, we need to evaluate the changes induced by hypoxia in the above ratios in Equation (4).

First, the ratio \[ \frac{Q_{mh}}{Q_{mn}} \] is the ratio of myocardial blood flow at maximal exercise between normoxia and hypoxia, for example, the “coronary reserve” that can be mobilized in hypoxia. Although there is no data in the literature above 4500 m, it is likely that coronary reserve is near maximal in normoxia and can hardly increase in hypoxia (Wyss et al., 2003). Therefore, this ratio is close to unity. In a second part of the study, we will evaluate the possible influence of a substantial increase in coronary reserve (see below).

Second, the ratio \[ \frac{Amh}{Amn} \] represents the intensity of the erythropoiesis induced by the prolonged exposure to high altitude. It is 1 in acute hypoxia and increases with acclimatization: For example, if [Hb] is 15 g/dl in normoxia and goes up to 20 g/dl in prolonged hypoxia, this ratio will be 1.33.

Third, the ratio \[ \frac{Samh - Svnm}{Samn - Svnn} \] represents the change in arterio-venous difference in O\textsubscript{2} saturation at maximal exercise from normoxia to hypoxia. We know from the literature that Samn is normally around 98% and that Svnn is around 30%, so that the arterio-venous difference in saturation in normoxia is around 68% (Heiss et al., 1976; Richalet et al., 1981). Altitude-induced changes in arterial O\textsubscript{2} saturation at maximal exercise are known from the literature. However, myocardial venous O\textsubscript{2} saturation at maximal exercise (Svnm) has never been measured yet.

Finally, the ratio \[ \frac{Amh}{Amn} \] depends on the ratio of energetic equivalents, the ratio of stroke volumes and the ratio of ejection pressures. Although no data is available, the energetic equivalent is probably not modified by altitude, unless profound changes in substrate utilization occur in hypoxia. Stroke volume is marginally modified in hypoxia: while a 10% decrease has been measured at rest, its value at maximal exercise at altitude (7620 m) has been estimated at 86% of its sea level value (Reeves et al., 1987; Sutton et al., 1988). Mean aortic pressure at exercise does not consistently increase at high altitude, while mean pulmonary pressure increases through pulmonary vasoconstriction (Boussuges et al., 2000). The sum of mean aortic + pulmonary pressures has been estimated to go from 153 mmHg at sea level to 150, 169 and 157 mmHg at 6100 m, 7620 m and 8840 m, respectively (Sutton et al., 1988). Altogether, the ratio \[ \frac{Amh}{Amn} \] probably stays around the unity since a decrease in stroke volume would compensate an increase in ejection pressures (Stembridge et al., 2016; Sutton et al., 1988).

Finally, if we summarize our first assumptions (no change in coronary reserve and compensations in variations of ejection volumes and pressures), we can write that:

\[ \frac{Q_{mh}}{Q_{mn}} \times \frac{Amh}{Amn} = 1 \] (5)

Therefore, combining Equations (4) and (5):

\[ HR_{mh} = \frac{[Hb]_{mh} \times (Samh - Svnm)}{[Hb]_{mn} \times (Samn - Svnn)} \]

Estimating Samn-Svnn at 68% (see above), we can calculate Svnm as a function of Samn as follows:

\[ Svnm = Samn - 68 \times \frac{HR_{mh} \times [Hb]_{mn}}{HR_{mn} \times [Hb]_{mh}} \] (6)
Samh can be estimated by linear regression from our data (Table 1, Figure 2) by the following equation:

\[ \text{Samh} = 107.6 - 0.0066 \times \text{Altitude (m)} \]  

Equation (6) then allows calculating myocardial venous O₂ saturation at maximal exercise in various altitude conditions if arterial O₂ saturation, heart rate, and hemoglobin concentrations are known. From O₂ saturation (SO₂), we can estimate O₂ pressure (PO₂), given a standard equation of the oxyhemoglobin dissociation curve and an estimated value of venous pH of 7.32:

\[ \text{PO}_2 = \frac{29.11 \times \text{SO}_2}{(100 - \text{SO}_2)^{0.3704}} \]

Dash et al. (2016) Therefore, we reach our main objective: estimating venous tissue O₂ pressure at maximal exercise at various altitudes and evaluating the influence of maximal heart rate on tissue oxygenation.

### 2.3 Summary of main assumptions

In order to build the present model, we made several assumptions, as follows:

- There is no significant increase in coronary reserve at high altitude (in a first approach).
- Arterio-venous difference in oxygen saturation in normoxia equals 68%.

| Reference                      | Altitude (m) | HR<sub>mh</sub> | Samh | [Hb]<sub>mh</sub> | Nb days |
|--------------------------------|--------------|----------------|------|----------------|---------|
| Moore et al. (1986)            | 4350         | 0.924          | 82   | 1.23           | 19      |
| Pugh et al. (1964)             | 4600         | 0.928          | 57   | 1.47           | 30–90   |
|                                | 5800         | 0.756          | 57   | 1.47           | 60–90   |
| Klausen et al. (1966)          | 3800         | 0.89           | 57   | 1.47           | 25      |
|                                | 4340         | 0.906          | 57   | 1.47           | 16      |
| Vogel et al. (1967)            | 4300         | 0.978          | 79.4 | 1.07           | 3       |
|                                | 4300         | 0.95           | 81.7 | 1.11           | 17      |
| Dill & Adams (1971)            | 3090         | 0.944          | 81.7 | 1.11           | 17      |
| Vogel et al. (1974)            | 4350         | 0.924          | 81.7 | 1.11           | 17      |
| Cerretelli (1976)              | 5350         | 0.87           | 81.7 | 1.11           | 17      |
| Horstman et al. (1980)         | 4300         | 0.963          | 79.4 | 1.07           | 3       |
| Saltin et al. (1968)           | 4300         | 0.946          | 79.5 | 1.13           | 15      |
| Dill et al. (1969); Klausen et al. (1970) | 3800 | 0.899          | 79.5 | 1.13           | 15      |
| Vogel et al. (1974)            | 4600         | 0.873          | 79.5 | 1.13           | 15      |
| Sutton et al. (1988)           | 6100         | 0.82           | 61   | 1.2            | 15      |
|                                | 7620         | 0.73           | 59   | 1.26           | 15      |
|                                | 8840         | 0.70           | 49   | 1.26           | 15      |
| Christensen & Forbes (1937)    | 5340         | 0.695          | 70   | 1.5            | 9–10    |
| Richalet (1983)                | 5000         | 0.859          | 70   | 1.5            | 9–10    |
| Richalet et al. (1988)         | 4350         | 0.952          | 90   | 1.23           | 8       |
|                                | 4800         | 0.901          | 90   | 1.23           | 8       |
| West et al. (1983); Winslow et al. (1984) | 6300 | 0.82           | 61   | 1.29           | 8       |
|                                | 8050         | 0.719          | 57   | 1.27           | 8       |
|                                | 8848         | 0.741          | 49   | 1.29           | 8       |
| Young et al. (1982)            | 4300         | 0.874          | 70   | 1.29           | 15      |
| Antezana et al. (1994)         | 6542         | 0.843          | 68   | 1.13           | 7       |
| Richalet et al. (1999); Robach et al. (2000) | 5000 | 0.85           | 77   | 1.1            | 2–6     |
|                                | 6000         | 0.785          | 72   | 1.07           | 9–12    |
|                                | 7000         | 0.75           | 68   | 1.14           | 15–19   |

\[ \frac{\text{HR}_{\text{mh}}}{\text{HR}_{\text{mn}}} \] : ratio of maximal heart rate measured at high altitude over value measured at sea level; \[ \text{Samh} \], arterial O₂ saturation at maximal exercise at high altitude; \[ \frac{[\text{Hb}]_{\text{mh}}}{[\text{Hb}]_{\text{mn}}} \] : ratio of hemoglobin concentration measured at high altitude over value measured at sea level; Nb days, number of days spent at high altitude.

| Table 1 Data from the literature was used to build the model of oxygen transport in the myocardium at maximal exercise in hypoxia |
• Decrease in stroke volume in hypoxia compensates an increase in ejection pressures.
• Coronary venous pH at exercise is 7.32.

2.4 | Data from the literature

In order to feed our model, we reviewed all available studies in the literature that simultaneously proposed values of heart rate, hemoglobin concentration, and arterial O₂ saturation for various altitudes above 4000 m at maximal exercise. Data from studies concerning prolonged exposure to hypoxia (>3 days) were included and studies concerning acute hypoxia were excluded. The first historical values come from the “International High Altitude Expedition to Chile” in 1935 (Christensen & Forbes, 1937). Values are presented in Table 1.

2.5 | Role of coronary reserve

Very few studies are available about coronary reserve at maximal exercise, especially at high altitude. Wyss and coworkers found no significant increase in acute hypoxia (4500 m) (Wyss et al., 2003). However, studies by Kaufmann and coll. have shown that it may increase by 20% at 4559 m (Kaufmann et al., 2008). To our knowledge, no value is available at higher altitudes. However, we evaluated how our model is modified, assuming that coronary reserve at maximal exercise may increase from sea level to high altitude. If we suppose that the minimal value of myocardial venous O₂ saturation compatible with adequate O₂ supply to the myocardium is 10% (Goodwill et al., 2017), we can calculate from Equations (4) and (7) the maximal altitude (maxAlt) compatible with this minimal O₂ saturation as a function of an estimated percentage increase in coronary reserve at maximal exercise (ΔQhn) from sea level:

\[
\text{maxAlt} = 14788 - \frac{8445}{\left(1 + \frac{\Delta Q_{hn}}{100}\right)} \quad (8)
\]

3 | RESULTS

Using equation (6) and Table 1, we can calculate Svmh in two scenarios:

1. Using the actual value of HRmh observed in the studies quoted in Table 1.
2. Considering that there is no decrease in HRmh at altitude, so that the ratio \(\frac{\text{HRmh}}{\text{HRmn}}\) is 1.

Results are shown in Figure 3.

Considering the second hypothesis of no decrease in maximal heart rate at altitude, venous O₂ saturation decreases with altitude and becomes negative above 8000 m, condition that is not physiologically compatible with life.
Similarly, values of venous PO₂ become negative around 8000 m (Figure 4).

In contrast, taking the first hypothesis, there is only a slight decrease in venous saturation and pressure but not as pronounced as for the first hypothesis (Figures 3 and 4).

Figure 5 shows that if we suppose that coronary reserve at maximal exercise is already maximal at sea level, the maximal reachable altitude compatible with myocardial euoxia is around 6200 m in case of no regulation of maximal heart rate. To reach the summit of Mount Everest without decrease in maximal heart rate, the increase in coronary reserve would have to be as high as 44.5%.

4 | DISCUSSION

The present model was constructed from the physiological data available in the literature. However, as expected, very few measurements are available in humans in those extreme conditions of exercise and altitude, so that we had to make some reasonable assumptions. To reduce the uncertainty of these assumptions, future studies may include measurements of myocardial blood flow, cardiac venous and mitochondrial PO₂ at maximal exercise, both at sea level and high altitude. Let us reconsider the above assumptions and estimate the effects on the results of a non-validity of some of them.

First, arterial hypoxemia is a probably the most powerful stimulus for coronary vasodilation, either directly or through active metabolites such as adenosine, NO or prostaglandins. However, hypoxia-induced vasodilation is limited (coronary reserve). If myocardial blood flow at maximal exercise can increase significantly at high altitude, let us suppose that the maximal value of ratio \( \frac{Q_{mh}}{Q_{mn}} \) is 1.2 (20% increase), as previously suggested (Kaufmann et al., 2008). In that condition, maximal altitude reachable would be around 7600 m (Figure 5). The minimal value of this ratio suitable to reach the summit of Mount Everest (8848 m) would be 44.5%, which is incompatible with our
FI G U R E 4 Calculated values of myocardial venous PO$_2$ ($PvO_2$) in the same conditions as in Figure 3. $Pv$ at maximal exercise stays almost constant, whatever the altitude, thanks to the autoregulation of maximal heart rate (see text for explanations). Negative values of $PvO_2$ are physiologically impossible in the case of the absence of regulation.

![Graph showing calculated myocardial PO$_2$ values vs. altitude](image)

$y = -3E-07x^2 + 0.0022x + 14.4$

$R^2 = 0.5467$ $p = 0.01$

$y = -1E-06x^2 + 0.0109x - 7.32$

$R^2 = 0.919$ $p < 0.001$

FI G U R E 5 Maximal reachable altitude compatible with normal myocardial oxygenation (myocardial venous O$_2$ saturation above 10%) as a function of an expected increase in coronary reserve at maximal exercise from sea level to high altitude, if we suppose that maximal heart rate does not decrease with altitude (no autoregulation). Note that if we consider that coronary reserve at maximal exercise is already maximal at sea level, the maximal tolerated altitude would be 6200 m. If we hypothesize a 20% increase in coronary reserve, the maximal altitude would be 7600 m. To reach the summit of Mount Everest (8848 m), the coronary reserve would have to increase by 44.5%.

![Graph showing maximal reachable altitude vs. expected increase in exercise coronary reserve](image)
present understanding of the regulation of myocardial blood flow and adequate myocardial oxygenation.

Second, if the increase in ejection pressures largely overpasses the decrease in stroke volume, the conditions would be worse for myocardial oxygenation, as inferred by Equation (4). Conversely, if pressures do not change and stroke volume largely decreases, conditions of oxygenation would be better, but this hypothesis is incompatible with values of ejection pressures and volumes available in the literature (Naeije, 2010; Stembridge et al., 2016; Sutton et al., 1988).

From the present modeling study, based on measured values from the literature, we suggest that the hypothesis of a preservation of maximal heart rate at high altitude at its sea level value would necessarily lead to values of myocardial tissue PO$_2$ incompatible with a viable myocardial oxygenation. Therefore, the alternative hypothesis of a mechanism limiting heart rate at exercise in hypoxic conditions therefore appears realistic (Figure 2). We hypothesize that cardiac chronotropic function could be controlled by a local mechanism linked to myocardial PO$_2$ (White et al., 1995). Several pathways have been mentioned in the literature. A downregulation of the adrenergic system has been shown in prolonged hypoxia, either in humans or animal models (Favret & Richalet, 2007). Adrenergic activation is well documented in acute and prolonged hypoxia (Antezana et al., 1994; Richalet et al., 1990) but the response to this activation is blunted as shown by a lower heart rate for a given value of plasma norepinephrine at exercise (Antezana et al., 1994; Richalet, Mehdioui, et al., 1988) or for a given value of perfused isoproterenol (Richalet, Larmignat, et al., 1988). In parallel, although a chronic exposure to 3500 m triggers a long-term reduction of the vagal tone at rest (Ponchia et al., 1994; Siebenmann et al., 2017), the parasympathetic system may be activated as shown by the restoration of heart rate at exercise after infusion of a muscarinic blocker (Bogaard et al., 2002; Boushel et al., 2001; Hlartley et al., 1974). In a model of rats exposed to prolonged hypoxia, the density of beta-adrenergic receptors has been shown decreased, while, conversely, the density of muscarinic receptors is increased (Kacimi et al., 1992, 1993; Voelkel et al., 1981). The complex pathway connecting adrenergic, muscarinic, and adenosinergic receptors to the adenylate cyclase in the cardiomyocyte is modified when exposed to hypoxia: the activity of the Gs protein is reduced while the expression of Gi protein is enhanced, both phenomenon leading to a blunting of adenylate cyclase activity and a reduced chronotropic function (Favret & Richalet, 2007; Fowler et al., 1986; Kacimi et al., 1995; León-Velarde et al., 2001; White et al., 1995). Moreover, an extensive evidence exists concerning the role of downregulation of adrenergic receptors in cardiac failure, another representative condition of imbalance between cardiac oxygen supply and consumption (Hamdani & Linke, 2012; Soltysinska et al., 2011). The heart is not the only organ where these desensitization mechanisms appear in hypoxia. Fat cells also show a decrease in their response to adrenergic activation in prolonged hypoxia (de Gloszewski et al., 1999). Renal handling of calcium is submitted to a down-regulation of parathormone effects in hypoxia (Souberbielle et al., 1995). Similarly, growth hormone production is subjected to a down-regulation of its specific receptor (Richalet et al., 2010). Lactate release by the muscle could be modulated by a down-regulation of beta-receptors (Reeves et al., 1992). Common elements in all these signaling pathways seem to be receptors regulated by a G protein complex (Hamdani & Linke, 2012; Richalet, 2016).

5 | CONCLUSION

Altogether, there appears to exist an integrated system at the cellular level that protects the myocardium from a hazardous disequilibrium between O$_2$ supply and O$_2$ consumption at high altitude. This system would fully explain the decrease in heart rate at maximal exercise at high altitude. This autoregulation of O$_2$ supply in the myocardium efficiently protects this vital organ against myocardial ischemia and its potentially serious clinical consequences (Richalet, 1997, 2016). Simple modeling of biological mechanisms may help for a better understanding of regulation systems in complex environmental conditions. This paper allows some significant advances in the knowledge of physiological adaptations to stressors such as hypoxia. It is a remarkable example of autoregulation of a vital organ submitted to a severe metabolic challenge that contributes to an overall process of homeodynamics (Hermand et al., 2021; Richalet, 2021). Future studies may include measurements of myocardial blood flow, cardiac venous, and mitochondrial PO$_2$ at maximal exercise, both at sea level and high altitude, to validate and refine our model.

ACKNOWLEDGMENTS

None.

CONFLICTS OF INTEREST

None.

AUTHORS CONTRIBUTION

Both authors contributed to data management and writing of the paper.
ORCID
Jean-Paul Richalet https://orcid.org/0000-0002-7110-008X
Eric Hermann https://orcid.org/0000-0002-3925-3393

REFERENCES
Antezana, A. M., Kacimi, R., Le Trong, J. L., Marchal, M., Abousahl, I., Dubray, C., & Richalet, J. P. (1994). Adrenergic status of humans during prolonged exposure to the altitude of 6,542 m. *Journal of Applied Physiology*, 76, 1055–1059. https://doi.org/10.1152/jappl.1994.76.3.1055

Bogaard, H. J., Hopkins, S. R., Yamaya, Y., Niizeki, K., Ziegler, M. G., & Wagner, P. D. (2002). Role of the autonomic nervous system in the reduced maximal cardiac output at altitude. *Journal of Applied Physiology*, 93, 271–279. https://doi.org/10.1152/japplphysiol.00323.2001

Bousquès, A., Molenat, F., Burnet, H., Cauchy, E., Gardette, B., Sainty, J.-M., Jammes, Y., & Richalet, J.-P. (2000). Operation everest III (Comex ’97): Modifications of Cardiac Function Secondary to Altitude-induced Hypoxia: An Echocardiographic and Doppler Study. *American Journal of Respiratory and Critical Care Medicine*, 161, 264–270. https://doi.org/10.1164/ajrccm.161.1.9902096

Cerretelli, P. (1976). Limiting factors to oxygen transport on Mount Everest. *Journal of Applied Physiology*, 40, 658–667. https://doi.org/10.1152/jappl.1976.40.5.658

Christensen, E. H., & Forbes, W. H. (1937). Der Kreislauf in großen Höhen. *Skand Arch Für Physiol*, 76, 75–87.

Dash, R. K., Korman, B., & Bassingthwaighte, J. B. (2016). Simple accurate mathematical models of blood HbO2 and HbCO2 dissociation curves at varied physiological conditions: evaluation and comparison with other models. *European Journal of Applied Physiology*, 116, 97–113.

de Glisezinski, I. E., Crampes, F., Harant, I. E., Havlik, P., Gardette, B., Jammes, Y., Souberbielle, J.-C., Richalet, J.-P., & Rivière, D. (1999). Decrease of subcutaneous adipose tissue lipolysis after exposure to hypoxia during a simulated ascent of Mt Everest. *Pflüg Arch - Eur J Physiol*, 439, 134–140. https://doi.org/10.1007/s004240051137

Dill, D. B., & Adams, W. C. (1971). Maximal oxygen uptake at sea level and at 3,090-m altitude in high school runners. *Journal of Applied Physiology*, 30, 854–859. https://doi.org/10.1152/jappl.1971.30.6.854

Dill, D. B., Horvath, S. M., Dahms, T. E., Parker, R. E., & Lynch, J. R. (1969). Hemococentration at altitude. *Journal of Applied Physiology*, 27, 514–518. https://doi.org/10.1152/jappl.1969.27.4.514

Favret, F., & Richalet, J.-P. (2007). Exercise and hypoxia: The role of the autonomic nervous system. *Respiratory Physiology & Neurobiology*, 158, 280–286. https://doi.org/10.1016/j.resp.2007.04.001

Favret, F., Richalet, J.-P., Henderson, K. K., Germack, R., & Gonzalez, N. C. (2001). Myocardial adrenergic and cholinergic receptor function in hypoxia: Correlation with O2 transport in exercise. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*, 280, R730–R738.

Fowler, M. B., Laser, J. A., Hopkins, G. L., Minobe, W., & Bristow, M. R. (1986). Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. *Circulation*, 74, 1290–1302. https://doi.org/10.1161/01.CIR.74.6.1290

Gnaiger, E., Steinlechner-Maran, R., Méndez, G., Eberl, T., & Margreiter, R. (1995). Control of mitochondrial and cellular respiration by oxygen. *Journal of Bioenergetics and Biomembranes*, 27, 583–596. https://doi.org/10.1007/BF02111656

Goodwill, A. G., Dick, G. M., Kiel, A. M., & Tune, J. D. (2017). Regulation of coronary blood flow. *Compr Physiol*, 7, 321–382.

Hamdani, N., & Linke, W. (2012). Alteration of the beta-adrenergic signaling pathway in human heart failure. *Current Pharmaceutical Biotechnology*, 13, 2522–2531.

Han, J.-C., Tran, K., Taberner, A. J., Chapman, B., & Loiselle, D. S. (2019). Chapter 23 - Cardiac Energetics. In J. A. Zoladz (Ed.), *Muscle and Exercise Physiology* (pp. 505–539). Academic Press. [Accessed November 3, 2021]

Hartley, L. H., Vogel, J. A., & Cruz, J. C. (1974). Reduction of maximal exercise heart rate at altitude and its reversal with atropine. *Journal of Applied Physiology*, 36, 362–365.

Heiss, H. W., Barmeyer, J., Wink, K., Hell, G., Cerny, F. J., Keul, J., & Reindell, H. (1976). Studies on the regulation of myocardial blood flow in man. I.: Training effects on blood flow and metabolism of the healthy heart at rest and during standardized heavy exercise. *Basic Research in Cardiology*, 71, 658–675. https://doi.org/10.1007/BF01906411

Hermand, E., Lhuissier, F., Pichon, A., Voituron, N., & Richalet, J.-P. (2021). Exercising in Hypoxia and Other Stimuli: Heart Rate Variability and Ventilatory Oscillations. *Life*, 11, 625. https://doi.org/10.3390/life11070625

Herrmann, S. C., & Feigl, E. O. (1992). Adrenergic blockade blunts adenosine concentration and coronary vasodilation during hypoxia. *Circulation Research*, 70, 1203–1216. https://doi.org/10.1161/01.RES.70.6.1203

Horstman, D., Weiskopf, R., & Jackson, R. E. (1980). Work capacity during 3-wk sojourn at 4,300 m: effects of relative polycythemia. *Journal of Applied Physiology*, 49, 311–318. https://doi.org/10.1152/japplphysiol.1980.49.2.311

Kacimi, R., Moalic, J. M., Aldashev, A., Vatner, D. E., Richalet, J. P., & Crozatier, B. (1995). Differential regulation of G protein expression in rat hearts exposed to chronic hypoxia. *American Journal of Physiology-Heart and Circulatory Physiology*, 269, H1865–H1873. https://doi.org/10.1152/ajpheart.1995.269.6.H1865

Kacimi, R., Richalet, J. P., Corsin, A., Abousahl, I., & Crozatier, B. (1992). Hypoxia-induced downregulation of beta-adrenergic receptors in rat heart. *Journal of Applied Physiology*, 73, 1377–1382. https://doi.org/10.1152/japplphysiol.1992.73.4.1377

Kacimi, R., Richalet, J. P., & Crozatier, B. (1993). Hypoxia-induced differential modulation of adenosinergic and muscarinic receptors in rat heart. *Journal of Applied Physiology*, 75, 1123–1128. https://doi.org/10.1152/japplphysiol.1993.75.3.1123

Kaufmann, B. A., Bernheim, A. M., Kiencke, S., Fischer, M., Sklenar, J., Mairbiurl, H., Maggiorini, M., & Brunner-La Rocca, H. P. (2008). Evidence supportive of impaired myocardial blood flow reserve at high altitude in subjects developing high-altitude pulmonary edema. *American Journal of Physiology-Heart and Comparative Physiology*, 280, R730–R738.
and Circulatory Physiology, 294, H1651–H1657. https://doi.org/10.1152/ajpheart.00760.2007
Klausen, K., Dill, D. B., & Horvath, S. M. (1970). Exercise at ambient and high oxygen pressure at high altitude and at sea level. Journal of Applied Physiology, 29, 456–463. https://doi.org/10.1152/jappl.1970.29.4.456
Klausen, K., Robinson, S., Michael, E. D., & Myhre, L. G. (1966). Effect of high altitude on maximal working capacity. Journal of Applied Physiology, 21, 1191–1194. https://doi.org/10.1152/jappl.1966.21.4.1191
León-Velarde, F., Bourin, M.-C., Germack, R., Mohammadi, K., Crozatier, B., & Richalet, J.-P. (2001). Differential alterations in cardiac adrenergic signaling in chronic hypoxia or norepinephrine infusion. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 280, R274–R281. https://doi.org/10.1152/japplregu.2001.280.1.R274
Mallet, R. T., Burtscher, J., Richalet, J.-P., Millet, G. P., & Burtscher, M. (2021). Impact of high altitude on cardiovascular health: current perspectives. Vascular Health and Risk Management, 17, 317–335. https://doi.org/10.2147/VHRM.S294121
Mollard, P., Woorons, X., Letournel, M., Lamberto, C., Favret, F., Pichon, A., Beaudry, M., & Richalet, J.-P. (2007). Determinants of maximal oxygen uptake in moderate acute hypoxia in endurance athletes. European Journal of Applied Physiology, 100, 663–673. https://doi.org/10.1007/s00424-007-0457-0
Moore, L. G., Cymerman, A., Huang, S. Y., McCullough, R. E., McCullough, R. G., Rock, P. B., Young, A., Young, P. M., Bloedow, D., & Weil, J. V. (1986). Propranolol does not impair exercise oxygen uptake in normal men at high altitude. Journal of Applied Physiology, 61, 1935–1941. https://doi.org/10.1152/jappl.1986.61.5.1935
Naeije, R. (2010). Physiological adaptation of the cardiovascular system to high altitude. Progress in Cardiovascular Diseases, 52, 456–466. https://doi.org/10.1016/j.pcad.2010.03.004
Opie, L. H. (1991). The heart: physiology and metabolism. Raven Press.
Ponchia, A., Noventa, D., Bertaglia, M., Carretta, R., Zaccaria, M., Miraglia, G., Pascotto, P., & Buja, G. (1994). Cardiovascular neural regulation during and after prolonged high altitude exposure. European Heart Journal, 15, 1463–1469. https://doi.org/10.1093/oxfordjournals.eurheart.a006415
Pugh, L. G. E., Gill, M. B., Lahiri, S., Milleld, J. S., Ward, M. P., & West, J. B. (1964). Muscular exercise at great altitudes. Journal of Applied Physiology, 19, 431–440.
Reeves, J. T., Groves, B. M., Sutton, J. R., Wagner, P. D., Cymerman, A., Malconian, M. K., Rock, P. B., Young, P. M., & Houston, C. S. (1987). Operation Everest II: Preservation of cardiac function at extreme altitude. Journal of Applied Physiology, 63, 531–539. https://doi.org/10.1152/jappl.1987.63.3.531
Reeves, J. T., Wolfel, E. E., Green, H. J., Mazzeo, R. S., Young, A. J., Sutton, J. R., & Brooks, G. A. (1992). Oxygen transport during exercise at altitude and the lactate paradox: Lessons from Operation Everest II and Pikes Peak. Exercise and Sport Sciences Reviews, 20, 275–296.
Richalet, J. P. (1983). The French scientific expedition to Numur, autumn 1981. Progress in Clinical and Biological Research, 136, 189–195.
Richalet, J.-P. (1997). Oxygen sensors in the organism: examples of regulation under altitude hypoxia in mammals. Comparative Biochemistry and Physiology Part A, Physiology, 118, 9–14.
Richalet, J.-P. (2016). Physiological and clinical implications of adrenergic pathways at high altitude. Advances in Experimental Medicine and Biology, 903, 343–356.
Richalet, J.-P. (2021). The invention of hypoxia. Journal of Applied Physiology, 130, 1573–1582.
Richalet, J. P., Larmignat, P., Rathat, C., Keromes, A., Baud, P., & Lhoste, F. (1988). Decreased cardiac response to isoproterenol infusion in acute and chronic hypoxia. Journal of Applied Physiology, 65, 1957–1961. https://doi.org/10.1152/jappl.1988.65.5.1957
Richalet, J.-P., Letournel, M., & Souberbielle, J.-C. (2010). Effects of high-altitude hypoxia on the hormonal response to hypothalamic factors. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 299, R1685–R1692.
Richalet, J.-P., Mehdouli, H., Rathat, C., Vignon, P., Keromes, A., Herry, J.-P., Sabatier, C., Tanche, M., & Lhoste, F. (1988). Acute hypoxia decreases cardiac response to catecholamines in exercising humans. International Journal of Sports Medicine, 09, 157–162. https://doi.org/10.1055/s-2007-1024997
Richalet, J.-P., Merlet, P., Bourguignon, M., Le-Trong, J. L., Kéromes, A., Rathat, C., Jouve, B., Hot, M. A., Castaigne, A., & Syrota, A. (1990). MIBG scintigraphic assessment of cardiac adrenergic activity in response to altitude hypoxia. Journal of Nuclear Medicine, 31, 34–37.
Richalet, J. P., Robach, P., Jarrot, S., Schneider, J. C., Mason, N. P., Cauchy, E., Herry, J. P., Bienvenu, A., Gardette, B., & Gorton, C. (1999). Operation Everest III (COMEX ’97). Effects of prolonged and progressive hypoxia on humans during a simulated ascent to 8,848 M in a hypobaric chamber. Advances in Experimental Medicine and Biology, 474, 297–317.
Richalet, J.-P., Soulard, C., Nitenberg, A., Teisseire, B., de Bovée, J., & Séroussi, S. (1981). Myocardial oxygen extraction and oxygen-hemoglobin equilibrium curve during moderate exercise. European Journal of Applied Physiology, 47, 27–39.
Robach, P., Déchaux, M., Jarrot, S., Vaysse, J., Schneider, J.-C., Mason, N. P., Herry, J.-P., Gardette, B., & Richalet, J.-P. (2000). Operation Everest III: Role of plasma volume expansion on VO2max during prolonged high-altitude exposure. Journal of Applied Physiology, 89, 29–37.
Rubio, R., & Berne, R. M. (1975). Regulation of coronary blood flow. Progress in Cardiovascular Diseases, 18, 105–122. https://doi.org/10.1016/0033-0620(75)90001-8
Saltin, B., Grover, R. F., Blomqvist, C. G., Hartley, L. H., & Johnson, R. L. (1968). Maximal oxygen uptake and cardiac output after 2 weeks at 4,300 m. Journal of Applied Physiology, 25, 400–409. https://doi.org/10.1152/jappl.1968.25.4.400
Siebenmann, C., Rasmussen, P., Hug, M., Keiser, S., Flück, D., Fisher, J. P., Hilty, M. P., Maggiorini, M., & Lundby, C. (2017). Parasympathetic withdrawal increases heart rate after 2 weeks at 3454 m altitude: Regulation of tachycardia in chronic hypoxia. Journal of Physiology, 595, 1619–1626.
Soltysinska, E., Thiele, S., Olesen, S. P., & Osadchii, O. E. (2011). Chronic sympathetic activation promotes downregulation of β-adrenoceptor-mediated effects in the guinea pig heart independently of structural remodeling and systolic dysfunction. Pflügers Archiv - European Journal of Physiology, 462, 529–543. https://doi.org/10.1007/s00424-011-1005-7
Souberbielle, J., Richalet, J., Garabedian, M., Sachs, C., & Déchaux, M. (1995). High-altitude hypoxia and calcium metabolism. In J. R. Sutton, C. S. Houston, & C. G. Burlington (Eds.), Hypoxia and the Brain (p. 336). Queen City Printers.
Stembridge, M., Ainslie, P. N., & Shave, R. (2016). Mechanisms underlying reductions in stroke volume at rest and during exercise at high altitude. *European Journal of Sport Science, 16*, 577–584. https://doi.org/10.1080/17461391.2015.1071876

Sutton, J. R., Reeves, J. T., Wagner, P. D., Groves, B. M., Cymerman, A., Malcomian, M. K., Rock, P. B., Young, P. M., Walter, S. D., & Houston, C. S. (1988). Operation Everest II: oxygen transport during exercise at extreme simulated altitude. *Journal of Applied Physiology, 64*, 1309–1321. https://doi.org/10.1152/jappl.1988.64.4.1309

Van Thienen, R., & Hespel, P. (2016). Enhanced muscular oxygen extraction in athletes exaggerates hypoxemia during exercise in hypoxia. *Journal of Applied Physiology, 120*, 351–361. https://doi.org/10.1152/japplphysiol.00210.2015

Voelkel, N. F., Hegstrand, L., Reeves, J. T., McMurty, I. F., & Molinoff, P. B. (1981). Effects of hypoxia on density of beta-adrenergic receptors. *Journal of Applied Physiology, 50*, 363–366. https://doi.org/10.1152/jappl.1981.50.2.363

Vogel, J. A., Hansen, J. E., & Harris, C. W. (1967). Cardiovascular responses in man during exhaustive work at sea level and high altitude. *Journal of Applied Physiology, 23*, 531–539.

Vogel, J. A., Hartley, L. H., Cruz, J. C., & Hogan, R. P. (1974). Cardiac output during exercise in sea-level residents at sea level and high altitude. *Journal of Applied Physiology, 36*, 169–172. https://doi.org/10.1152/jappl1974.36.2.169

Wagner, P. D. (2010). The physiological basis of reduced VO2max in operation everest II. *High Altitude Medicine & Biology, 11*, 209–215.

West, J. B., Boyer, S. J., Graber, D. J., Hackett, P. H., Maret, K. H., Milledge, J. S., Peters, R. M., Pizzo, C. J., Samaja, M., Sarnquist, F. H., et al. (1983). Maximal exercise at extreme altitudes on Mount Everest. *Journal of Applied Physiology, 55*, 688–698. https://doi.org/10.1152/jappl.1983.55.3.688

White, M., Yanowitz, F., Gilbert, E. M., Larrabee, P., O’Connell, J. B., Anderson, J. L., Renlund, D., Mealey, P., Abraham, W. T., & Bristow, M. R. (1995). Role of beta-adrenergic receptor down-regulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy. *American Journal of Cardiology, 76*, 1271–1276. https://doi.org/10.1016/S0002-9149(99)80355-5

Winslow, R. M., Samaja, M., & West, J. B. (1984). Red cell function at extreme altitude on Mount Everest. *Journal of Applied Physiology, 56*, 109–116.

Wyss, C. A., Koeplfl, P., Fretz, G., Seebauer, M., Schirlo, C., & Kaufmann, P. A. (2003). Influence of altitude exposure on coronary flow reserve. *Circulation, 108*, 1202–1207. https://doi.org/10.1161/01.CIR.0000087432.63671.2E

Young, A. J., Evans, W. J., Cymerman, A., Pandolf, K. B., Knapik, J. J., & Maher, J. T. (1982). Sparing effect of chronic high-altitude exposure on muscle glycogen utilization. *Journal of Applied Physiology, 52*, 857–862. https://doi.org/10.1152/jappl.1982.52.4.857

**How to cite this article:** Richalet, J.-P., & Hermand, E. (2022). Modeling the oxygen transport to the myocardium at maximal exercise at high altitude. *Physiological Reports, 10*, e15262. https://doi.org/10.14814/phy2.15262